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Abstract:
Objectives 
Due to the nature of the condition, health technology assessment 
agencies might face considerable challenges in choosing appropriate 
outcome measures for Alzheimer’s disease drugs. To analyse which 
outcome measures were used in past health technology assessments in 
three European countries: England, Germany, and The Netherlands; to 
explore possible reasons for prioritisations, and derive potential 
implications for future assessments of Alzheimer’s disease drugs. 
Method 
We conducted a literature review of studies that analysed decisions 
made in health technology assessments (across disease areas) in the 
three European countries. We then conducted case studies of technology 
assessments conducted for Alzheimer’s disease drugs in these countries. 
Results 
Overall, outcomes measured using clinical scales dominated decisions or 
recommendations about whether to fund Alzheimer’s disease drugs, or 
price negotiations. Health technology assessment processes did not 
always allow the inclusion of outcomes relevant to people with 
Alzheimer’s disease, their carers and families. Processes did not include 
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early discussion and agreement on what would constitute appropriate 
outcome measures and cut-off points for effects. 
Conclusions 
To facilitate consistent and timely decisions about the value of new 
Alzheimer’s disease drugs early agreement with various stakeholders 
about outcomes, outcome measures and cut offs is important to ensure 
that future AD drugs are appropriately valued. 
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Due to the nature of Alzheimer’s disease, health technology assessment agencies might face 
considerable challenges in choosing appropriate outcomes and outcome measures for drugs 
that treat the condition. This study sought to understand which outcomes informed 
previous health technology assessments, to explore possible reasons for prioritisations, and 
derive potential implications for future assessments of Alzheimer’s disease drugs.
Method
We conducted a literature review of studies that analysed decisions made in health 
technology assessments (across disease areas) in three European countries: England, 
Germany, and The Netherlands. We then conducted case studies of technology assessments 
conducted for Alzheimer’s disease drugs in these countries.
Results 
Overall, outcomes measured using clinical scales dominated decisions or recommendations 
about whether to fund Alzheimer’s disease drugs, or price negotiations. Health technology 
assessment processes did not always allow the inclusion of outcomes relevant to people 
with Alzheimer’s disease, their carers and families. Processes did not include early 
discussion and agreement on what would constitute appropriate outcome measures and 
cut-off points for effects. 
Conclusions
We conclude that in order to ensure that future Alzheimer’s disease drugs are valued 
appropriately and timely, early agreement with various stakeholders about outcomes, 
outcome measures and cut-offs is important.
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Many countries face the prospect of rapid increases in expenditure related to Alzheimer’s 
disease (AD). Governments are faced with the task of making decisions about which drugs 
and interventions should be funded. Health technology assessment agencies or other 
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decision-making bodies are responsible for such decisions based on reviews of clinical and 
effectiveness or cost-effectiveness evidence through a process called health technology 
assessment (HTA). Assessing the effectiveness or cost- effectiveness for approved AD drugs 
has been difficult because AD drugs have historically promised only very small or no effects 
in functional improvement or modifying disease progression (1,2). Whilst HTA processes 
vary by country, they have in common that evidence on effectiveness or cost-effectiveness 
is reviewed by a technical team and interpreted by a group of stakeholders, who present 
different perspectives such as those of clinicians, drug companies, patient representatives 
and researchers. Which outcomes and outcomes measures influence final decisions is likely 
to be based on various criteria including: whether they reflect meaningful changes in a 
person’s life (which is important from the perspective of people living with the condition, 
their families and carers); whether they are measurable in study designs (which is 
important from a developer and manufacturer perspective); and whether they are clinically 
and economically relevant (which is important from a payer perspective). Processes leading 
to decisions are complex, and are likely to vary between countries. The aims of our study 
were to understand: (1) which outcomes and outcomes measures are likely to be prioritized 
in HTAs for AD drugs in different countries, and (2) which processes influence these 
priorities. This study complemented other work which sought information on outcome 
prioritization from the perspective of patients, carers and practitioners (3, 4).
Methods
Overall approach and selection of countries
Page 6 of 49
Cambridge University Press
International Journal of Technology Assessment in Health Care
For Peer Review
6
We employed two methods: a literature review and case studies. Findings of the literature 
review informed the design of the case studies. Both methods are explained in more detail 
below.  Researchers with methodological expertise in systematic reviews (CT, AL) and 
qualitative research interviews (MN) as well as researchers specialized in medicine and 
neurology (CS), with knowledge of drug reimbursements and of HTA processes (CB, AG), 
and of dementia policies and economics (MK, RW) were involved in reviewing the methods 
throughout the research.  In addition, the advisory group of the larger research programme 
of which this study was a part and which consisted of members from HTA or regulatory 
agencies across the world commented formally on initial findings. Three European 
countries were selected: England, Germany and The Netherlands. The respective HTA 
agencies are the National Institute for Health and Care Excellence (NICE) in England, the 
Institute for Quality and Efficiency in Health Care (IQWiG) in Germany and the Dutch 
Zorginstituut Nederland (ZIN). The choice was influenced by the size of the economy and 
roles and responsibilities of HTA agencies with the aim to have multiple perspectives: 
England and Germany present two large economies in Europe, in which HTA agencies have 
taken on different roles and responsibilities. For example, hereas in England drugs need 
to be cost-effective in order to be publicly funded (5,6), in Germany decisions about 
whether drugs are funded and at what price are primarily based on their added therapeutic 
benefit (7). The Netherlands, as a relatively small economy in Europe, has taken a middle 
ground approach in this regard: the cost-effectiveness of drugs needs to be proven if their 
cost is above a certain threshold (8). An overview of the main features of the HTA agencies 
in the three different countries is shown in Table 1.
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--- Table 1 about here ---
Data collection and analysis
First, we conducted a literature review of studies which analyzed how outcomes are 
prioritized during HTA processes in the three countries. For the purpose of the literature 
review, we pragmatically defined prioritized outcomes (and their measures) as those that 
informed the final decision about whether the drug gets funded, or about its price. We 
made this decision based on initial searches, which showed how the issue has been 
investigated in the literature of HTAs. Since we expected that there would be limited 
evidence from the AD field, we searched for studies across disease areas. Details on search 
strategies, review and data extraction methods can be found in Supplement 1. Second, we 
gathered data on how outcomes and outcome measures had been prioritized in past HTAs 
of AD drugs. We conducted case studies based on information available on HTA websites, 
which documented the decision processes from the beginning to final recommendation. 
Here, we conceptualized ‘prioritization’ as the process of deriving decisions about which 
outcomes and measures should inform the value of AD drugs. We therefore considered any 
evidence of how decisions were made including views and opinions expressed by 
stakeholders about the importance of certain outcomes and measures, and how they 
thought they should inform the decision about the value of AD drugs. Information was 
extracted on topics relevant to outcomes and outcome measures considered in the 
appraisal. The framework for case studies and the data extraction form can be found in 
Supplement 2. The analysis was a thematic one, in which we used a mix of inductive and 
deductive methods for deriving themes. 
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About the data sources
Our literature review identified a total of 32 studies for the three countries. Thirteen 
studies referred to England; fourteen to Germany (this included one study which also 
referred to England); and six to The Netherlands. Studies used the following types of 
methods: quantitative analysis using statistical methods (n=10); qualitative or mixed 
methods (n=16); literature reviews (n=3); opinion papers or editorials (n=4). The main data 
sources were HTA reports and documentation of the decision processes from HTA agencies’ 
websites and interviews. Details of studies can be found in Supplement 3.
The case studies referred to publicly available documentation of HTAs for AD drugs 
(cholinesterase inhibitors and memantine) carried out between 2006 and 2010 in each of 
the three countries. This included altogether 6 HTAs: England (n=1; covering cholinesterase 
inhibitors and memantine together); Germany (n=2; one for cholinesterase inhibitors and 
one for memantine); Netherlands (n=3; memantine; donzepil; rivastigmine for Parkinson’s 
disease). What was documented varied widely between HTAs and countries but covered at 
a minimum: 
 draft and final scope (including an agreed set of outcomes and outcome 
measures); 
 draft and final appraisal of the reviewed evidence (including decisions or 
recommendations); 
 consultation comments by stakeholders to draft scope and appraisal.
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The list of documents that were identified as well as a list of stakeholders involved in the 
HTA processes can be found in Supplements 4 and 5; no documentation was available for 
stakeholder consultation in the Netherlands’ HTAs. 
Results
A range of evidence related to relevant outcomes and outcome measures was collated under 
eight themes. The purpose of the collation was to have distinguishable themes that reflected 
the different aspects covered in the case studies and the literature. The themes are related 
and to a certain degree overlapping. The findings for each will be described in turn, and we 
refer in brackets to the numbered data source, which can be found in the Supplements 3 and 
4.
Cost-effectiveness
In England, decisions about whether to fund AD drugs were based on cost-effectiveness, 
which in turn was based on health-related quality of life (in the form of quality adjusted life 
years measured with the EQ-5D) and institutionalization (Suppl. 4: 4.5). No other economic 
consequences (e.g. for hospital care) were included or discussed. Both, health-related 
quality of life and institutionalization, were in additional analysis extrapolated from clinical 
scales for cognition and functioning (Suppl. 4: 4.1; 4.2). In Germany and in The Netherlands, 
no additional economic analysis and no review of economic evidence was conducted, and 
there was no mention of cost-effectiveness in the scoping documents (Suppl. 4: 4.12; 4.13; 
4.17-1.19). This partly reflects the different approaches in the three countries towards 
including cost-effectiveness evidence in HTAs (Suppl. Table 1: 3.5): Germany does not 
include cost-effectiveness in their HTAs. In The Netherlands, the prices of the drugs were 
considered ‘too low’ to justify the need for cost-effectiveness considerations i.e. as long as 
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they had additional value and no adverse consequences they would be funded (personal 
communication with ZIN representative). 
Quality of Life (QoL)
There were differences in the ways HTA agencies responded to challenges of measuring 
QoL for people with AD: NICE allowed the prediction of QoL in the form of economic 
modelling based on surrogate outcomes measured with clinical scales. This approach was in 
contrast to the one taken by IQWiG, which does not accept the use of QoL measures like 
the EQ-5D and which has been consistently found to rarely accept QoL evidence (Suppl. 
Table 3: 3.14 3.21; 3.23; 3.25). Methodological requirements (such as a minimum follow up 
rate of 70%) frequently lead to the exclusion of evidence. Based on this and other 
methodological requirements not met by studies, IQWiG concluded that the evidence of an 
impact of AD drugs on QoL was insufficient (Suppl. Table 4: 4.14-4.16; 4.23-4.25). The 
resulting exclusion of QoL outcomes in the appraisal of AD drugs was criticized by some of 
the stakeholders (Suppl. Table 4: 4.12; 4.15; 4.16; 4.18; 4.19; 4.21). ZIN, whilst generally 
accepting and prioritizing QoL evidence including when measured through the EQ-5D [8], 
did not review QoL evidence in their HTAs of AD drugs (Suppl. Table 4: 4.26-4.28). We were 
unable to find an explanation.
Outcomes measured with clinical scales (O-CS)
A wide range of outcomes were measured with clinical scales. Table 2 presents an overview 
of the scales used in studies reviewed for the technology assessments. Not all scales, 
however, informed the advice or decisions about the value of AD drugs equally.  In all three 
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countries O-CS such as cognition (measured, for example, with the Alzheimer's Disease 
Assessment Scale-cognitive subscale; ADAS-cog) or functioning (measured, for example, 
with Activities of Daily Living scales; ADL) had an important influence on final decisions 
(Suppl. 4: 4.4; 4.15; 4.24).  In the HTAs in England there was less evidence of stakeholder 
discussion about their relevance to people with AD (Suppl. 4: 4.7-4.10). The surrogate 
nature of those outcomes was made explicit in NICE’s documentation (Suppl. 4: 4.1-4.4). 
The debate about the relevance of O-CS for people with AD was strongest in German HTAs 
(Suppl. 4: 4.20; 4.21). Whilst manufacturers argued the importance of clinical outcomes - in 
particular cognition - as reliable indicators of QoL with good psychometric properties, some 
stakeholders doubted whether clinical scales measured something that was meaningful to 
individuals (Suppl. 4: 4.20; 4.21). Both, IQWiG and the Federal Joint Committee 
(Gemeinsamer Bundesausschuss; G-BA), the body that makes the final and legally-binding 
decision about which drugs are funded, appeared to treat all O-CS as final health outcomes 
(Suppl. 4: 4.12-4.14), which meant that they bypassed some of their stricter methodological 
requirements that would have applied if they had been treated as surrogate outcomes 
(Suppl. Table 3: 3.24; 3.27). In terms of specific measures, IQWiG did not accept the use of 
global assessment outcomes (measured for example with the Clinician Interview-Based 
Impression of Change; CIBIC), which were seen as reflecting the clinician’s perspective 
rather than the perspective of the person with AD (case studies). Instead, they expressed a 
preference for measures which evaluated personal goal attainment such as the Goal 
Attainment Scale (Suppl. 4: 4.14). ZIN pragmatically accepted those O-CS that had been 
accepted by the European Medicines Agency as validated outcome measures (Suppl. Table 
3: 3.22; Suppl. 4: 4.26-4.28). This excluded the Mini-Mental State Examination (MMSE) as a 
measure for cognition, which was in contrast to NICE, which accepted its use as a main 
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outcome measure for modelling final QoL endpoints (Suppl. 4: 4.3;4.4; 4.26-4.28). ZIN 
noted that the wide range of outcome measures across different domains made the 
comparison of findings from studies difficult (Suppl. 4: 4.26-4.28).
--- Table 2 about here ---
During HTAs of AD drugs in all three countries, stakeholders raised concerns about how to 
interpret the identified (often very small) changes on clinical scales (Suppl. 4: 4.7-4.11; 4.16; 
4.20). Several stakeholders argued that there was need for greater clarity, from the 
beginning, on cut-off points on various scales (Suppl. 4: 4.7-4.11; 4.16; 4.20). They should: 
be based on evidence, reflect disease severities, and be relevant to people with dementia. 
NICE tried to address the challenge of low effect sizes by giving particular weight to multi-
domain changes (i.e., a simultaneous change in different scales). IQWiG considered every 
single outcome separately and as a result came to more conservative conclusions about the 
value of drugs (i.e. they concluded more uncertainty about their effectiveness), resulting in 
criticism from the drug manufacturers (Suppl. 4: 4.16; 4.20). In the Netherlands, ZIN 
expected manufacturers to set out and justify relevant cut-offs before conducting studies 
(Suppl. 4: 4.26-4.28). Responding to the uncertainty over clinical relevance and relevance to 
people with AD, it decided to make the introduction of the drugs subject to start and stop 
criteria and delegated the application of those to clinicians (Suppl. 4: 4.26-4.28).
Adverse effects
In England, benefit-harm considerations were not given much weight during HTAs possibly 
because safety concerns were addressed already as part of market authorization and 
aspects of adverse effects were thought to be captured in QoL outcomes (Suppl. Table 3: 
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3.11). Some stakeholders felt that the better tolerability of AD drugs, when compared to 
alternative treatments (such as antipsychotics), was undervalued in this approach (Suppl. 4: 
4.11). In contrast, adverse effects were regarded as important outcomes from the 
perspective of people living with AD in Germany and the Netherlands (Suppl. 4: 4.14; 4.16; 
4.26-4.28). Stakeholders of the HTAs carried out by IQWiG criticized the lack of long-term 
safety data on AD drugs and raised concerns about whether adverse effects had been 
underestimated (Suppl. 4: 4.11). In The Netherlands, ZIN sometimes left benefit-harm 
decisions to clinicians, as it concluded that the evidence did not support general 
conclusions (Suppl. 4: 4.26-4.28).
Outcomes relevant to people with AD
In both England and Germany, stakeholders (mainly patient representatives but also 
researchers and commissioners) argued that many outcomes relevant to people with AD 
were not being picked up by the clinical scales (Suppl. 4: 4.2; 4.8; 4.11; 4.21; 4.23; 4.25). 
They advocated for including more tangible outcomes (e.g. ability for someone to pick up 
the phone) as well as long-term outcomes (e.g. institutionalization). An ability to maintain 
aspects of personal identity was seen as another important outcome. Stakeholders 
highlighted an urgent need for appropriate outcome measures in early stages of AD (Suppl. 
4: 4.8; 4.11). 
In both countries, stakeholders thought that this required more flexible approaches 
towards including evidence (Suppl. 4: 4.8; 4.21; 4.23; 4.25). Whilst this need for different 
and more flexible processes was to a large extent shared by NICE, in Germany IQWiG and 
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G-BA believed that such changes would contradict legislation and reduce the necessary 
methodological robustness (Suppl. 4: 4.21; 4.23; 4.25). 
In the Dutch HTAs for AD drugs, the challenges of considering outcomes that mattered to 
people with AD, their carers and families were not documented but had been - according to 
a ZIN representative - discussed at several stages of the process (personal communication). 
Carers’ outcomes 
In NICE’s HTAs of AD drugs, carers’ QoL was a primary outcome or endpoint (Suppl. Table 4: 
4.1; 4.3), reflecting the priority given by NICE to this group. However, final decisions were 
based on an economic model, which did not include carers’ outcomes, an omission which 
was criticised by some stakeholders (Suppl. 4: 4.7; 4.11). In Germany, carers’ outcomes 
were not viewed as the responsibility of the healthcare system and were given lower 
priority relative to outcomes for people with AD (Suppl. 4: 4.21; 4.25). Whilst some 
stakeholders argued for including carers’ outcomes in its own right, there seemed to be an 
overall consensus that carers’ outcomes were important mainly because of their impact on 
the person with AD (Suppl. 4: 4.21; 4.25). In addition, IQWiG was skeptical about carer-
reported outcomes for the person with dementia, which they argued reflected the needs of 
the carer rather than the needs of the person with dementia (Suppl. 4: 4.21; 4.25). Dutch 
HTAs for AD drugs did not include carers’ outcomes (Suppl. 4: 4.26-4.28). 
Institutionalization 
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Institutionalization for someone with AD was a stated outcome in HTA agencies’ 
documentation and discussed as important by stakeholders in Germany and England 
(Suppl. 4: 4.1; 4.3; 4.12; 4.13; 4.17-4.19). Only English HTAs included institutionalization as 
an outcome in the economic modelling although stakeholders discussed whether it was 
possible to accurately predict this outcome since there were many other correlated factors 
such as the carer’s situation and availability of care in the community (Suppl. 4: 4.8) . In 
German HTAs institutionalization was viewed by some stakeholders as an outcome that was 
primarily important from an economic perspective (Suppl. 4: 4.21; 4.25). Some stakeholders 
thought that ’institutionalization’ could not be measured separately from ‘time spent 
caring’, and that instead ‘hours of care provided’ should be measured independently of 
whether they were provided by a professional or by an unpaid carer (Suppl. 4: 4.21; 4.25). 
Similar to the discussion in English HTAs, stakeholders discussed the lack of evidence on 
these outcomes and methodological challenges of including them. In The Netherlands there 
was no recorded information on these outcomes.
Table 3 presents an overview of the findings. We applied categories indicating if an 
outcome or group of outcomes was prioritized or not prioritized. ‘Prioritized’ outcomes 
were those that informed decisions and ‘Not prioritized’ outcomes were those that did not 
inform decisions. 
---- Table 3 about here ----
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This study assessed the outcomes and outcome measures that dominated HTAs of AD drugs 
in three European countries, and the processes that influenced those priorities. This is to 
our knowledge the first study, which examines how outcomes and measures for AD drugs 
are currently prioritised in technology assessments. This study contributes to an increased 
transparency about reasons for and challenges of including certain outcomes when 
assessing the value of AD drugs. Overall, we identified some challenges in the process of 
how outcomes, outcome measures and cut-off points were defined in technology 
assessments of AD drugs. This included a lack of early involvement of stakeholders in 
discussions of appropriate outcomes and outcome measures as well as of cut-off points for 
appropriate effect sizes.  In addition, a narrow focus on evidence from certain types of 
studies, namely randomised controlled trials, led to a strong focus on outcomes measured 
with clinical scales to the potential exclusion of (long-term) outcomes relevant for people 
with AD. 
Our study was exploratory in nature, and we chose to conduct two methods to address the 
gap in evidence about the role of outcomes and outcome measure in HTAs of AD drugs. We 
first reviewed studies that analysed the influence of outcomes and measures on decisions of 
the value of drugs in HTAs. Whilst this provided useful knowledge about common decision 
making patterns in HTAs (and reasons for those), it provided only limited information about 
the process, by which decisions were made about outcomes and measures, and the process 
by which they influenced decisions. Whilst we have no affirmative knowledge of the reason 
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for this missing focus of studies, it is plausible that decisions about outcomes and measures 
are regarded objective or neutral. It is also likely to reflect a wide acceptance of outcomes 
measured with clinical scales as patient-relevant. As a result, designers of studies and 
manufacturers have to make decisions about outcomes and measures without certainty 
whether those will be accepted by HTAs. In the case of HTAs for AD drugs, this is likely to 
have contributed to the use of a wide range of measures. With the second method, the case 
studies, we therefore sought to address the gap in evidence about the process by which 
outcomes and measures are influencing decisions through in-depth analysis of reports 
produced for technology assessments.  This kind of analysis allowed us to understand the 
nature of decision processes, and stakeholder viewpoints. Although this study was 
explorative in nature, we were able to shed new light on the important, currently under-
investigated role of outcomes and outcome measures in influencing the value of AD drugs.
In terms of methodological robustness, the literature review, although pragmatic, applied 
systematic search strategies and involved detailed data extraction. Researchers with a high 
and diverse level of methodological and clinical expertise were involved in and contributed 
to the robustness of the research process. Approval of the research methods and 
interpretation of the findings was provided by experts in the field. In terms of limitations, 
for the case studies, we were reliant on publicly available information, which was limited, 
especially for the Dutch case studies. Furthermore, by focusing on HTAs with the most 
comprehensive information and those that were most comparable between countries, we 
might have missed some aspects of more recent updates of HTAs. Overall, our findings 
need to be interpreted in the context of a rapidly evolving field. Considerations that 
decision makers need to take into account today may very well change in the future, for 
example in light of new evidence and new technologies. 
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The findings from this study suggest that there are substantial challenges in including 
outcomes relevant to people with AD when assessing the value and cost-effectiveness of AD 
drugs. Those challenges are not only relevant to existing AD drugs but to other types of 
treatment and interventions, which seek to prevent or alter the progression of AD. Unless 
there is an agreed set of outcomes, outcome measure and cut-offs that define a meaningful 
diversion from the path without intervention, it will be challenging to assess the value of a 
drug or an intervention (in particular in relation to other interventions). In the future, this is 
likely to be relevant to pricing or investment decisions for disease-modifying treatments, 
which may need to be offered at pre-dementia stages, and which would require measuring 
surrogate outcomes such as imaging or other biomarkers (9). Without outcome measures 
that are acceptable to relevant stakeholders – including patients, carers and the wider 
public - and agreed before HTAs are conducted or preferably even before studies are being 
developed, there is a risk of delays in the appropriate evaluation of, and access to, new 
treatments (10). Clear methodological guidance on accepted outcome measures in fields 
such as prevention and diagnostics is therefore needed (11). 
This includes the need to consider patient-relevant outcomes in HTAs in addition to clinical 
outcomes (12). Whilst in early stages, innovative methods have been developed (and 
tested) that allow HTA agencies to consider patient preferences over different outcomes 
when developing methodological guidance (12). Knowledge is also becoming increasingly 
available about how to best include patient and carers’ perspectives in HTAs (13). Decisions 
about the value of drugs in HTAs in some countries (including England) have shown to be 
substantially influenced by aspects of value not captured by clinical and economic evidence 
(14). Whilst this is a reflection of including patient and stakeholders perspectives it also 
raises questions about transparency and consistency of decisions (14).Therefore, including 
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outcomes, measures and cut-offs that are more patient-relevant (and agreeing on those in 
advance) is likely to contribute to more consistent decision making as it reduces the need 
for additional considerations that in effect address the issue of evidence not being 
sufficiently relevant to what matters to patients, carers and the wider public.
Furthermore, the challenges we identified suggest a need for collaborative approaches 
between multiple stakeholders to enable decisions on outcomes and measures to be made 
early in the process. Some of the required processes are already in place, to varying degrees 
in different countries, whilst others still need to be developed. 
Such multi-stakeholder approaches should go hand in hand with including wider sets of 
evidence, often referred to as real-world evidence (15). This requires an investment in data 
that can be used to demonstrate long-term impact on costs and outcomes (1). This might 
include data on the costs associated with different rates of disease progression so that cost 
savings linked to a delay in disease progression can be estimated. Findings from a study that 
modelled the likely cost-effectiveness of disease-modifying treatments (should they become 
available) showed that in England the benefit from deferring onset by one year would be 
substantial at about £28,000 (in 2012/13 prices) (16). This highlights the importance of 
including such data in decision making. Unless the impacts on disease progression, QoL, 
need for care and costs over time are considered, there is a risk that that future AD drugs 
and interventions are not valued in line with patient, carers and wider public interests. 
Conclusions
This study investigated the role of outcomes and outcome measures in HTAs of AD drugs in 
three European countries. The findings highlight the strong priority placed on outcomes 
measured with clinical scales as well as the challenges of considering measures that capture 
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changes in disease progression that are potentially relevant from the perspective of people 
living with the condition, their families and carers. We conclude that there is an urgent need 
to reform HTA processes to appropriately assess the value of AD drugs. 
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Table 1:  Features of health technology assessment (HTA) agencies in England, Germany, 
and The Netherlands
Table 2: Clinical scales used in studies identified in health technology assessments (HTAs) of 
Alzheimer’s disease drugs in England, Germany, and The Netherlands
Table 3: Prioritization of outcomes and outcome measures in health technology 
assessments (HTAs) of Alzheimer’s disease (AD) drugs 
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Supplement 1: Details on search strategies, inclusion and exclusion criteria, 
data extracted and quality appraisal
The following databases were searched for articles published between 2007 and November 
2017: CINAHL, MEDLINE, SocScience, EconLit, Elsevier Science Direct. The following subject 
headings and keywords were used: outcome-related term (i.e. outcome OR benefit OR 
effect OR endpoint) AND country-related term (i.e. Germany OR Netherlands OR England) 
AND a technology assessment-related term (i.e. benefit assessment OR technology 
assessment). If the number of results was particularly large, we added an additional search 
term for decision making process (i.e. process OR decision making). 
In addition, the smart search (CINAHL), recommendations based on previously read articles 
(Elsevier Direct) and articles frequently cited together (PubMed) functions of databases 
were used. Additional searches in journals of particular relevance such as ‘Value in Health’ 
and ‘Medical Decision Making’ were also carried out. A few reference searches for key 
articles were carried out to test if all relevant articles were captured in the searches.
Articles were included that referred to decisions, processes and standards of health 
technology assessments if they made reference to the role of outcomes. Excluded were 
articles, which were critical discussions about the use of specific methods - such as: the 
quality-adjusted life years (QALY) measure; social discount rates in economic evaluation 
methods; multi-criteria decision making – or which related to personalised medicine, 
described the influence of HTA processes on market access to drugs or focused on price 
setting mechanisms and negotiations. 
The following information was extracted for each study: study ID; setting; purpose; design; 
type of data and analysis method; further details about methods (where required); results; 
conclusions and limitations stated by author(s). For each study a rating was generated to 
reflect its relevance for our research questions. 
In a next step, information was summarised for each country using the following headings 
(which were identified during the initial analysis of information): 
 Responsibilities of HTA and other relevant agencies in regards to HTA or 
reimbursement process; 
 HTA process and requirements; 
 Decision making process and criteria; 
 Price negotiations and status of listing decision; 
 Stakeholder involvement in process; 
 Surrogate and composite outcomes; 
 Quality of life (and quality-adjusted life years); 
 Cost-effectiveness; 
 Sub groups.
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Supplement 2: Case study framework and data extraction form 
Case study framework
Case studies were carried out for health technology assessments / appraisals (HTA) carried 
out in the dementia/ AD field in three countries: England, Germany and Netherlands.
For England the case study referred to one Multiple Technology Appraisal for donezepil, 
galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (AD)1, 
which was published 23 March 2011 with last update 11 May 2016. Relevant publicly 
available documents were included to inform the case studies, such as:
 Guidance and appendices; 
 Research recommendations information;
 Documents produced as part of the guidance development such as: 
o Background information (includes review decision documents, press 
releases);
o Assessment report documents;
o Draft and final protocol documents;
o Draft and final matrix documents;
o Draft and final scope documents (including consultation comments);
o Appraisal consultation documents (e.g. Assessment reports; Consultee and 
commentator comments on the assessment report; Manufacturer and Non-
manufacturer Submissions; Expert written personal statements;
o Final appraisal determination documents (including comments on appraisal 
consultation
In Germany case studies referred to the following 3 single drug benefit assessments: 
Memantine in AD; Cholinesterase inhibitors in AD; Ginkgo compounds. There were no 
technology appraisals in form of early benefit assessments carried out for dementia/ AD 
drugs since introduction of the new legislation (AMNOG) in 2011. Instead, all appraisals 
refer to drug assessments carried out before AMNOG. Relevant information included the 
following documents from the IQWiG website:
 Final and preliminary reports 
 Documentation and appraisal of comments on the preliminary report 
 Report plan (different versions) and amendments
 Documentation and appraisal of comments on the report plan 
 Executive summary of the working paper ‘Memantine in Alzheimer’s disease: Results 
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We also looked at the G-BA website for manufacturers’ value decisions, G-BA value 
decisions (Tragende Gruende). Further information about decisions and the role of clinical 
endpoints in those decisions were also available online2 3 4 5.
In The Netherlands, case studies referred to short pharmacotherapeutic reports for 
donezepil (for the indication and symptomatic treatment of mild to moderately severe 
Alzheimer’s dementia)6; rivastigmin for people with Parkison’s disease and memantine.
Across case studies, the following information were extracted with respect to the following 
questions:
Which endpoints were set out during scoping?
Which primary endpoints were used in studies that supported the 
recommendation? (This might include information about categorised 
clinical endpoints and clinical scales)
Which surrogate endpoints were used that supported 
recommendations, which methods of validation were used? Did the 
Committee discuss the appropriateness of surrogate endpoint as 
validated indicators of endpoints?
How were patient preferences (satisfaction, adherence, complaints) and 
patient reported outcomes considered?
Which endpoints were considered in cost-effectiveness analysis that 
supported recommendations?  How was clinical evidence mapped to 






Were aspects of meaningful delay and disease progression considered in 
endpoints?
Which suggestions were made in regards to clinical endpoints? 
Which challenges around including relevant clinical endpoints were 
discussed by stakeholders?





Which clinical endpoints were identified as relevant for future research?
Uncertainty How did uncertainty in data influence discussions about outcome? Were 
there any criteria or rationales that made an uncertain outcomes more 
acceptable? 
Which thresholds were applied in regards to clinical measures and/or 
cost-effectiveness?
Threshold
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For each HTA, information was extracted from publicly available documentation relating to 
the HTA using a range of categories that were derived from headings used in analysis of data 
from the literature review and from an initial analysis of the information. The categories 
were as follows:
Outcomes included:
 Outcomes set out during scoping
 Outcomes considered during review
 Outcomes considered differently as a result of stakeholder involvement (Suggestions 
made by stakeholders in regards to outcomes) 
 Outcomes identified as relevant for future research
 Outcomes used in studies that supported the recommendation
 Outcomes considered in cost-effectiveness analysis
Challenges around including outcomes: 
 Types of evidence considered
 Surrogate outcomes and methods of validation
 Patient preferences and patient-reported outcomes
 Aspects of meaningful delay and disease progression
 Influence of data uncertainty on outcomes
 Thresholds in regards to outcomes measures or cost-effectiveness
Supplement 3: Details of studies identified in literature review 
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Purpose Setting Method Data sources Details Results Limitations
England (N=13)
3.1 Allen et al 
2017 (Low)




the initial decisions of 
the other HTA 
agencies, and to 
identify factors for 
differing national HTA 
recommendations 






Medicines that were 
reviewed by all four 
agencies and received a 
negative recommendation 
from only one agency 
were selected as case 
studies. Statistical analysis 
of HTA recommendations 


















HTA agencies and 
responsible body for 
reimbursement 
decision
HTA bodies considered clinical 
efficacy; adverse effects; cost-
effectiveness; all have implicit or 
explicit quality-adjusted life-year 
threshold; factors influencing 
decisions were: uncertainties 
surrounding a range of factors 
including: cost-effectiveness; 
comparator choice; clinical 
benefit; safety; trial design; 
submission timing
Use of publicly 
available sources; 
inclusion criteria 
limited to products 
listed on Controlled 
Drug Regulation, 
which resulted in 
exclusion of cancer 
medicines
3.2 Carroll et 
al 2017 
(Medium)
To explore the type of 
additional exploratory 
analyses conducted 
by Evidence Review 
Groups and their 
impact on the 
recommendations 
made by NICE
England A content analysis of 
relevant documents was 
undertaken to identify and 
extract relevant data, and 
narrative synthesis was 
used to rationalize and 
present these data.












research team; this 
was used to inform 
coding; all data 
extraction were 
double checked by 
two researchers
The additional analyses 
undertaken by Evidence Review 
Groups in the appraisal of 
company submissions are highly 
influential in the policy-making 
and decision- making process; 
clear influence on 47% of final 
appraisal determinations
No limitations stated 
by author(s)
3.3 Cerri et al 
2013 (High)
This study examined 
the impact of 
evidence, process and 
context factors on 
NICE decisions; to 
assess which of 
factors best explains 
the pattern of NICE 
decisions
England With multinomial logistic 
regression, the relative 
contribution of explanatory 
variables on NICE 
decisions was assessed
A data set of NICE 
decisions 2004-















Results showed significant 
associations (p<0.10) between 
NICE decision outcome and four 
variables: (i) demonstration of 
statistical superiority of the 
primary endpoint in clinical trials 
by the appraised technology; (ii) 
the incremental cost-
effectiveness ratio (ICER); (iii) 
the number of pharmaceuticals 
appraised within the same 
appraisal; and (iv) the appraisal 
year. 
No limitations stated 
by author(s)
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3.4 Clement et 
al 2009 (High)





(including any barrier 
to such use) and what 





Descriptive analysis of 
retrospective data from 
HTA bodies; 3 case 
















points as clinical 
endpoints, or 
surrogate endpoints; 
for surrogate end 
points, authors 
determined whether 
the committee felt 
the surrogate was a 
valid predictor of 
changes in the 
relevant clinical end 
point
Factors that influenced 
decisions: The differences in 
listing decisions often appeared 
less about the interpretation of 
the clinical or economic evidence 
and more about differences in 
agency processes In terms of 
outcomes: More than 50% of 
submissions reviewed by NICE 
used clinical end points (rather 
than clinical scales or 
surrogates), and if surrogate 
outcome were used they were 
more likely to be judged valid by 
committee
Use of publicly 
available sources; 
there may be subtle 
issues that were not 
captured, 









3.5 Dakin et al 
2014 (Medium)
To investigate the 
influence of cost-
effectiveness and 
other factors on NICE 
decisions and whether 
NICE’s decision-
making has changed 
over time
England Logistic regression to 
predict whether a 
technology was 
recommended or not; 
NICE’s decisions as binary 
choices for/ against a 
technology in a specific 
patient group



















Cost-effectiveness was main 
driver for NICE decisions; past 
decisions appear to have been 
based on a higher threshold than 
£20 000–£30 000/QALY; this 
may reflect consideration of 
other factors that cannot be 
easily quantified.












England Opinion paper - - No direct conclusions; issues 
discussed around QALY, ICER, 







Opinion paper that 
explores HTA 
approaches, in both 
methods and policy, to 
help bring about 
reconciliation between 
Europe Opinion paper - - HTA initiatives are likely to give 
manufacturers an incentive to 
more closely align their research 
and development with social 
objectives; adequate stakeholder 
involvement is needed to ensure 
N/A
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different parties and 
focus on social values 
and patient 
perspective
that the values incorporated in 




To structure empirical 
evidence of coverage 
decisions made in 
practice based on the 
components ‘methods 








Literature review Electronic 
databases, 




between 1993 and 
June 2011. 
Included were 





Each study was 
categorized by the 
scope of decision-
making and the 
components 
covered by the 
variables used in 
quantitative 
analysis.
Important influence of 
therapeutic value where decision 
makers did not explicitly account 
for cost-effectiveness; the ICER 
had significant influence on 
decisions in Canada, Australia 
and the UK, but usually in 
combination with other aspects 
such as burden of disease or 
health condition. Budget 
considerations were significant 
influences in Australian and 
Dutch decision-making.
No limitations stated 
by author(s) 
3.9 Kreis and 
Schmidt 2013 
(Low)
This article explores 
operational processes 
and underlying 
rationales of public 









and underlying rationales 
The analysis is 





grey literature, and 
semi structured, 
in- depth 
interviews with top 
officials at these 
agencies
Authors used the 
term public as the 
broadest generic 




(or us rs), 
laypeople, or formal 
or informal 
representatives of 
groups of these 
Engagement processes differed 
across agencies, particularly 
regarding the areas in which the 
public is involved, which groups 
of the public are involved, what 
weight they have in influencing 
decisions, how they are recruited 
and supported, and how 
potential conflicts of interests are 
addressed. 





To identify diverging 
HTA 
recommendations 
across five countries, 
understand the 
rationale for decision-
making, and suggest 










analysis of HTA 
recommendations for 287 
drug-indication pairs 
appraised by countries 
between 2007 and 2009, 
including an in-depth 






using kappa scores. 
Associations 
between the HTA 
recommendations 




Substantial disparities in 
recommendations for/ against 
drugs; HTA processes potentially 
influenced by: different priorities 
in different settings; different 
perception of benefit and value, 
and use of different tools of 
addressing uncertainty; patient 
preferences and characteristics 
No limitations stated 
by author(s)
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seem to weigh more heavily in 
certain disease areas than other
3.11 Nicod et 
al 2017 (High)
To better understand 
the reasons for 
differences in 
reimbursement 
decisions for orphan 






Semi structured interviews 










An interview topic 
guide was 
developed on the 
basis of findings 
from a systematic 
comparison of HTA 
decisions for 10 
orphan drugs. 
Qualitative thematic 
data analysis using 
the framework 
approach
Decisions regarding orphan 
drugs made in context of lower 
quality evidence; threshold of 
acceptable uncertainty varied by 
country; NICE more likely to 
accept surrogate endpoints for 
orphan drugs; NICE always 
prefers overall survival to 
progression-free survival; 
HRQOL data were considered 
as a hard end point by NICE. 
Safety only implicitly considered 
because already part of 
marketing authorisation. 
No limitations stated 
by author(s)
3.12 Oyebode 
et al 2016 
(Low)
To determine the 
aspects of expert 
advice that decision-
makers find most 
useful in the 
development of 
evidence-based 
guidance and to 
identify the 
characteristics of 
experts providing the 
most useful advice
England (1) Interviews examined 
the usefulness of expert 
advice during guidance 
development. 
(2) Associations between 
usefulness score and 
characteristics of the 
expert advisor were 
investigated using 




interviews with 17 






(2) Data were 





(1) Transcripts were 
analysed inductively 
to identify themes; 
(2) Usefulness of 
advice was scored 
using an index 
developed through 
the qualitative work.
Values and challenges of using 
expert opinion in HTA processes 
are analysed
Authors reflect on 
their own potential 
bias due the 
researchers’ 
previous experience 
at NICE and working 







et al 2013 
(Medium)
To assess whether 
different clinical 
evidence bases may 






Authors reviewed the 
evidence considered for 
each listing 
recommendation, 
identified the similarities 
and differences, and 
evaluated the extent to 
which different clinical 
Appraisal reports 




nine drugs for 
which the three 
agencies had 
Not provided Decisions across HTA bodies 
associated with differences in 
the clinical evidence base 
considered. NICE considered 
indirect and/or mixed-treatment 
comparisons; in some cases, 
NICE excluded trials from review 
if the drug and/or the comparator 
Small number of 
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were not administered according 
to the relevant marketing 
authorization.
Germany (n=14)




requirements for QoL 
measurement and 
data presentation in 
early benefit 
assessment (EBA)
Germany Qualitative content 
analysis based on 
documents of all EBAs 
completed by 2014; 
analysis included 
information extraction, 











IQWiG or Federal 
Joint Committee 
(G-BA); protocol of 
the oral hearing; 






searched for the 
term QoL; Relevant 
passages of all 
EBAs of 2011–2013 
were independently 
extracted and 
reduced to key 
content by two 
researchers. 
Recurring patterns 




No association between the 
inclusion of QoL data in benefit 
dossiers and the G-BA’s rating 
decision might be explained by 
non-compliance with the various 
methodological requirements 
found in our analysis, so that in 
most cases, the mere inclusion 
of QoL data in the dossier did 
not lead to a positive evaluation 
of QoL benefit. In addition, many 
EBAs did include QoL outcomes, 
but there were no statistically or 
clinically significant effects





To explain the 
decisions made in 
early benefit 
assessments (EBAs), 









Germany Authors evaluated 
differences in rating 
decisions by 
manufacturers, the IQWiG, 
and the G-BA with regard 
to each pharmaceutical’s 
added benefit. 
Authors used Cohen’s 
kappa to analyze 
agreement between rating 
decisions; chi-square test 
and bivariate regression 
were used to identify 
associations between 
components of the EBA 
Data extracted for 
EBAs for which 
the G-BA made a 
rating decision 









the process; types 
of evidence 
submitted; 






compared to identify 
any deviations. 
Interrater reliability 
was good, with an 
average Cohen’s 
kappa coefficient of 
0.63 (range, 0.28 to 
1.00) for categorical 
variables and an 
average Pearson’s 
correlation 
coefficient of 0.80 
While the G-BA tended to 
disagree with the rating of 
benefit by manufacturers, it 
softened IQWiG’s decisions, 
potentially to make the final 
outcome more acceptable. 
Concerns voiced that the G-BA 
might be exceeding its statutory 
authority by taking cost or 
procedural considerations into 
account appear to be 
unfounded. Choosing 
appropriate evidence to submit 
for each endpoint remained a 
challenge, as submission of 
No limitations stated 
by author(s)
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health outcomes evidently 
influenced decisions.
3.16 Fischer et 
al 2016 
(Medium)
To analyse whether 
decisions of the 
German regulatory 
agency (G-BA) 
deviate from decisions 
from HTA or 
regulatory agencies in 
England (NICE), 











made for comparable 
patient subgroups by the 
four agencies between 
2011 and 2014. First, 
decisions were compared 
(a) by their final outcome, 
i.e. whether a health 
benefit was identified, and 
(b) by the agencies’ 
judgement on comparative 
effectiveness. 
Subsequently, they 
partially explored reasons 
for differences between 
HTA agencies.






for G-BA decisions 

















G-BA and each of 





Kappa, to determine 
whether agreement 
between two raters 
was by chance
G-BA deviated considerably in 
decisions compared to other 
HTA agencies; G-BA tends to 
appraise stricter than NICE.
HTA Agencies differed in 
accepting endpoints such as 
recognising the surrogate 
endpoint progression-free-
survival. Another example is to 
prefer disease-specific mortality 
over over-all mortality as 
endpoint or vice versa. Other 
factors in which agencies were 
different: choice of 
comparator(s); differences in 
handling lack of evidence
Agreement in endpoints between 
the agencies was highest for 
adverse events and quality of life 
followed by mortality; for 
morbidity, G-BA and the other 
agencies agreed least often 
No limitations stated 
by author(s) 
3.17 Ivandic et 
al 2014 (High)
To explore to which 
extent methodological 






The following aspects 
were examined: guidance 
texts on methodology and 
information sources for the 
assessment; clinical study 
design and methodology; 
statistical analysis, quality 
of evidence base, 
extrapolation of results 
(modelling), and 









The findings are 
presented 
separately for the 
two HTA systems 





to highlight the main 
similarities and 
Methodological requirements 
differed mainly in the acceptance 
of low-level evidence, surrogate 
endpoints, and data modeling. 
Some of the discrepancies may 
be explained, at least in part, by 
differences in the health care 
system and procedural aspects 
(e.g. timing of assessment).
No limitations stated 
by author(s)
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of outcome






Analysis of past 
decisions of German 
HTA to inform future 
submissions  
Germany All IQWiG decisions from 
January 2011 to May 2015 
were assessed, and the 
effect of the clinical 
evidence base on the 




from Jan 2011 to 
May 2015
Recommendation 
(‘added benefit’ or 
‘no added benefit’), 
indication, rationale, 
and evidence base 
were extracted
Over half of drugs appraised by 
IQWiG since 2011 have been 
given ‘no added benefit’ status, 
and direct evidence against an 
appropriate comparator remains 
a priority for a favourable 
decision
No limitations stated 
by author(s)
3.19 Kohler et 
al 2015 
(Medium)
To determine the 




for methods and 
results of studies 
available at market 
entry of new drugs.
Germany Authors assessed 
reporting quality for each 
study and each available 
document for eight 
methods and 11 results 
items  For each document 
type they calculated the 
proportion of items with 
complete reporting for 
methods and results, for 





IQWiG between 1 







Not provided Concludes that AMNOG 
documents provide a 
considerably higher proportion of 
complete information than 
European public assessment 
reports; this includes information 
on methods, results and patient 
relevant outcomes. The 
information gap was most 
striking when the drug was 




et al 2014 
(Low)
To describe the 
feasibility of the early 
benefit assessment on 
the basis of patient-
relevant outcomes by 
systematically 
characterising the 









Germany Dossier assessments 
were used for data 
extraction; the outcomes 
available and the 
respective evaluations 
were extracted and 
compared. 12 out of 22 
submitted dossiers 
contained sufficient data to 
assess outcomes; all 12 
assessable dossiers 






October 2011 and 
June 2012
Not provided Data on mortality and adverse 
events were available in almost 
all dossiers; data on morbidity 
and health-related quality of life 
available in 8 and 7 dossiers, 
respectively. Of a total of 214 
outcomes extracted by IQWiG, 
124 patient-relevant and 3 
surrogate outcomes were 
included in IQWiG’s assessment 
(companies: a total of 183 
outcomes included, of which 172 
were patient-relevant and 11 
were surrogates outcomes partly 
deviated from each other. 
No limitations stated 
by author(s) 
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To analyze how value 
is determined within 




Germany Generalized linear model 
regression to analyze 
impact of added benefit on 
difference between 









in Germany before 
June 30, 2016
Data were extracted 
from G-BA 
databases; added 
benefit was defined 
in various ways; in 
all models, they 
controlled for 
additional criteria 
such as size of 
patient population, 
European price 
levels, and whether 
the comparators 
were generic.
Authors conclude that price 
premiums were driven by health 
gain, the proportion of people 
benefitting from a 
pharmaceutical, European price 
levels, and whether the 
comparator was generic. QoL 
did not play a role in current 
decision making









with special attention 




extent of benefit, 
determination of net 
benefit, primary and 
secondary endpoints, 
and uncertainty of the 
additional benefit.
Germany Authors state they contrast 
the approaches taken by 
the G-BA and IQWiG with 
those of the European 






Code Book, and 















overview and opinion on 
methodological requirements 
and issues in German HTA 
process, with particular focus on 
the role of outcomes and 
evidence types 
No limitations stated 
by author(s)
3.23 Lohrberg 
et al 2016 
(High)
To analyse how QoL 
is defined in early 
benefit assessment 
(EBA) and which role 
does it play
Germany Qualitative analysis all 
benefit assessments 
completed by the end of 
2013 were processed. 
Additionally, data on the 







protocols of the 
oral hearings, the 
final resolutions of 




imported to software 
and searched for 
QoL terms; resulting 
paragraphs were 
reduced and 
summarized by two 
researchers; coding 
was performed on 
the basis of 
summaries
QoL has not been well defined in 
HTA processes and does not 
inform final decisions; they 
identified the absence or the 
inappropriate presentation of 
QoL data; at the same the 
stakeholders saw the value and 
importance of including QoL in 
EBA
No limitations stated 
by author(s)
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2013 (n = 66)
3.24 Riedel et 
al 2014 (Low)
To explain some 
fundamental concepts 
in Health Economic 
Evaluations (HEE) 
and how these 
concepts are adapted 





Bibliographic search to 
identify existing methods 
of health economic 
evaluation of new drugs 
used by HTA agencies in 
11 countries and 




- Although the core principles of 
HEE are very similar worldwide, 
there is a lack of harmonization. 
Overcoming the fourth hurdle 
(the reimbursement hurdle) is 
likely to be increasingly 
challenging for new drugs. 
No limitations stated 
by author(s)
3.25 Ruof et al 
2014 (a) (High)
To analyse the 
outcomes 18 months 
after introduction of 
the new AMNOG 
legislation on early 
benefits assessments 
(EBA) 
Germany All EBAs commenced prior 
to June 2012 were 
included and analysed 
(proportions were 
calculated; no statistical 
analysis was carried out)











27 EBAs were 
analysed in regards 






Considerable variance was 
observed in additional benefit 
reported by manufacturers, 
IQWiG and G-BA. Areas of 
disagreement included 
comparator selection, definition 
of subgroups and patient-
relevant endpoints, and 
classification and balancing of 
adverse events.
No limitations stated 
by author(s) 
3.26 Ruof et al 
2014 (b) (High)
To compare endpoints 
and related benefit 
categories used in 
marketing 
authorisation to those 
considered by G-BA in 
the field of oncology
Germany Evaluation of early benefit 
assessments (EBAs) in 
oncology commencing 
prior to 31 December 2013
The Summary of 
Product 
Characteristics 




derived from the 









derived from (i) the 
SPCs, (ii) 
manufacturers’ 
value dossiers and 
(iii) the G-BA value 
decisions 
Inconsistencies in acceptance of 
morbidity and QoL outcomes 
between G-BA and EMA; EMA 
accepted well established and 
clinically relevant morbidity 
endpoints (e.g. progression-free 
survival and response rate), 
which were mostly excluded by 
G-BA; final decisions by G-BA 
mostly driven by mortality 
outcomes
No limitations stated 
by author(s)
3.27 Staab et 
al 2016 (High)
To evaluate the 
acceptance of 
clinically 
Germany Medicines for oncological, 
metabolic and infectious 







Inconsistencies were identified in 
patient relevance of morbidity-
related PEPs as well as in 
No limitations stated 
by author(s) 
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from regulatory trials 
in early benefit 
assessments (EBAs) 
conducted by the 
Federal Joint 
Committee (G-BA) 
finalised before 25 
January 2016 were 
evaluated. 
assessments, G-











outcomes were also 
analysed
acceptance of asymptomatic 
endpoints by the G-BA
Netherlands (N=6)
3.28 Angelis 
et al 2017 
(High)
To study the 
practices, processes 
and policies of value-
assessment for new 
medicines across 
eight European 
countries and the role 
of HTA beyond 
economic evaluation 










A systematic (peer review 
and grey) literature review 




structure of HTA 
agencies’; (2) ‘Evidence 
and evaluation criteria 
considered in HTAs’; (3) 
‘Methods and techniques 










through the Web 
of Science portal) 
were searched up 
to January 2014; 
with article 
searches taking 
place in February 
2013 in the first 
instance and 
update taking 




based on the Centre 
for Reviews and 
Dissemination 
(CRD) guidance 
Feedback from the 
Advance-HTA 
consortium partners 
was provided in 
August 2014. 
Additional input, 
including the most 
recent updates on 
national HTA 
processes, was 
collected from HTA 
experts and national 
competent 
authorities between 
March and May 
2016.
Debates about health utilities/ 
preferred health gain; for 
example, while NICE favours the 
use of the QALY, IQWiG strongly 
opposes its use on the grounds 
that it does not reflect patient-
level utilities
Increasing use of incorporating 
real world data; considerable 
subjectivity in the criteria 
selection used to interpret 
evidence and determine product 
value; increasing realisation by 
many HTA agencies that value is 
multi-dimension; move away 
from only relying on ‘scientific 
value judgments’ (safety/ 
efficacy/ effectiveness); need for 
methodological approaches that 
encompass multiple evaluation 
criteria explicitly.
No limitations stated 
by author(s) 
3.29 Cerri et al 
2014 (Medium)
To examine the 
factors that influence 
decisions made by the 
Dutch HTA agency 
(CVZ) to recommend, 
restrict or not 
recommend 
pharmaceutical 
Netherlands Descriptive statistics for 
each variable, stratified by 
outcome group 
(recommended, restricted 
or not recommended): chi-
squared test for 
categorical variables; 
ANOVA test for 
continuous variables; 
CVZ decisions in 
2004–2009. A 








included in list 
1A/1B or on the 
expensive drug list 
considered 
recommended; 
those included in list 
The multinomial model showed 
significant associations (p B 
0.10) between CVZ outcome 
and several variables, including: 
(1) use of an active comparator 
and demonstration of statistical 
superiority of the primary 
endpoint in clinical trials, (2) 
pharmaceutical budget impact 
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technologies for use in 
the Netherlands
Kruskal-Wallis for not 
normally distributed 
indicators. 
A multinomial logit 
regression was used in the 
analysis to model the 
probabilities associated 






2 were considered 
restricted; 
associated with introduction of 
the technology, (3) therapeutic 
indication and (4) prevalence of 
the target population. Results 
confirm the value of a 
comprehensive and multivariate 
approach to understanding CVZ 
decision-making. 
3.30 Franken 
et al 2013 
(Medium)
To investigate the role 
of pharmacoeconomic 
evidence in drug 
reimbursement 
decision making; and 
(ii) to determine the 
extent to which 
appraising the 
importance of full 
economic evaluations 
relative to other 




Authors investigated all 
reimbursement dossiers 
published in the period 
January 2005 to July 
2011. 
Data sources 
included all Dutch 
and Swedish drug 
reimbursement 
information 
published in the 
period January 
2005 to July 2011
The analysis started 
in 2005 because 
that was the first 





decision making in 
The Netherlands.
Therapeutic value appeared to 
be the most decisive criterion; 
the relative importance of full 
economic evaluations is more 
modest than would generally be 
expected, especially in The 
Netherlands; both countries 
could make the appraisal 
process more transparent by 
more explicitly showing the role 
of different criteria.
Reliance on publicly 
available data 
sources
3.31 Le Polain 
et al 2010 
(Medium)
To describe and 
critically evaluate drug 
reimbursement 
decision processes, to 
identify their strengths 
and weaknesses and 









Comparative study (1) for 
the description of drug 
reimbursement decision 
processes, authors used 
the Hutton framework; (2) 
systems were evaluated 
using accountability for 
reasonableness 






- The paper provides a wide range 
of information on assessment 
and appraisal processes of 
Dutch HTA, and draws 
conclusions about criteria: For 
example, although there is no 
formal hierarchy in assessment 
criteria, most interviewees stated 
that effectiveness, efficacy and 
side effects were often the most 
important criteria determining the 
therapeutic value. Interviewees 
also acknowledged that the 
majority of time in a meeting of 
the Dutch HTA is devoted to 
determining the therapeutic 
value, less time is spent on 
Analysis took place 
in supply-driven 
context; it was 
beyond the scope of 




system, where the 
societal needs drive 
the industry’s 
strategic plan 
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3.32 Stolk et al 
2009 (Medium)
To review the current 
approach to HTA used 
in The Netherlands in 
medical specialist 
care; the authors seek 
to provide a basic 
understanding of the 
strengths and 
weaknesses of the 
specific practices and 
processes 
Netherlands Opinion paper - - Authors explore trends in future 
of (Dutch) HTA: What can be 
expected is a growing incentive 
for all parties to generate HTA 
data; increasing trend for 
conditional reimbursement linked 
to requirements for data 
collection and further study; 
further work is needed to 
understand how assessments 
and procedures jointly affect 
decision-making and to develop 
best practice guidelines; broader 
appraisals might be needed 
where the assessment will also 
cover optimal positioning of a 
service amongst the variety of 






In this editorial, the 
authors highlight the 
distinguishing features 
of the new Dutch 
guidelines for 
economic evaluation; 
and highlight which 
developments, in their 
opinion, are desirable 
in coming updates, 
but are still in 
development or 
controversial
Netherlands Editorial - - New guidelines set preference 
for QALYs measured with the 
EQ-5D if appropriate but also 
offer alternative approaches for 
areas in which QoL might not be 
appropriate such as: prevention; 
diagnostics; medical devices; 
long-term care; forensics; 
reference is also made to multi-
criteria decision making
N/A
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Supplement 4: HTA documents analysed for case studies 
National Institute for Health and care Excellence (NICE), England
Draft documents for consultation
4.1 Health Technology Appraisal Donepezil, galantamine, rivastigmine and memantine for the treatment of mild to moderate 
Alzheimer's disease (Part review of TA 111) Draft scope
4.2 Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review): appraisal consultation document (online)
Final documents
4.3 Health Technology Appraisal Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease 
(Review of TA 111) Final Scope
4.4 Final Appraisal Determination Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease 
(review of NICE technology appraisal guidance 111)
Reports by the Assessment group
4.5 The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of 
Alzheimer’s disease (review of TA111): a systematic review and economic model, Produced by: Peninsula Technology Assessment 
Group (PenTAG), University of Exeter [Note that this includes a revised section on results]
4.6 Overview Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease   (Review of NICE 
technology appraisal guidance 111)
Comments to Technology Assessment Report (TAR)
4.7 Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (Review of TA 111), Responses by 
various stakeholders including: Eisai/Pfizer; NHS Quality Improvement Scotland; NHS West Kent and NHS Islington;  Novartis; Shire 
Pharmaceuticals; Alzheimer’s Society; RICE (The Research Institute for the Care of Older People); Lundbeck 
Responses by Assessment Group
4.8 NICE Health Technology Appraisal, Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's 
disease (review of TA 111), Response to consultee and commentator comments on the draft remit and draft scope
4.9 NICE, Health Technology Appraisal, Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's 
disease (review of NICE technology appraisal guidance 111)   Response to consultee, commentator and public comments on the 
Appraisal Consultation Document (ACD)
4.10 AChEIs and memantine for Alzheimer’s Disease, PenTAG responses to Consultee comments 17th August 2010
Submissions
4.11 Various submissions including by manufacturers and other stakeholders e.g. Alzheimer’s Society Report; British Geriatrics 
Society; Royal College of Psychiatrists (Faculty of old age psychiatry); NHS Quality Improvement Scotland
Institut für Qualität und Wirtschaflichkeit im Gesundheitswesen (IQWiG), Germany
Cholinesterase Inhibitors: Donezepil, Galantamin, Rivastigmin 
4.12 Berichtsplan zum Bericht „Cholinesterasehemmer bei Alzheimer Demenz“ , [Auftrag A05-19A], Version 1.0 Stand: 02. Juni 2005; 
Report plan. Last accessed 10th January 2018
4.13 Amendment 1 zum Berichtsplan „Cholinesterasehemmer bei Alzheimer Demenz“, [Auftrag A05/19A] , 12.06.2006; Amendment 
1 to Report Plan version 1.0. Last accessed 10th January 2018
4.14 IQWiG. Cholinesterasehemmer bei Alzheimer Demenz. Vorbericht A05/19-A. Köln: Institut für Qualität und Wirtschaftlichkeit 
im Gesundheitswesen (IQWiG); September 2006. [Preliminary report] Last accessed 10th January 2018 
4.15 IQWiG: Cholinesterase inhibitors in Alzheimer’s disease. Final report A05-19A. Cologne: Institute for Quality and Efficiency in 
Health Care (IQWiG); February 2007. Last accessed 10th January 2018
4.16 IQWiG. Cholinesterasehemmer bei Alzheimer Demenz. Abschlussbericht A05-19A. Köln: Institut für Qualität und 
Wirtschaftlichkeit im Gesundheitswesen (IQWiG); Februar 2007. Last accessed 10th January 2018 [ this is the German version of 
4.15; in addition to 4.15 it includes the documented stakeholder involvement through meeting and written consultation] 
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Accord Healthcare (donepezil) Novartis (rivastigmine)
Aspire Pharma (galantamine, rivastigmine) Pfizer (donepezil)
Actavis UK (all four drugs) Ranbaxy (donepezil)
Consilient Healthcare (galantamine, memantine) Sandoz (all four drugs)
Dr Reddy’s Laboratories (all but galatamine) Shire (galantamine)
Eisai (donepezil) Teva UK (all four drugs)
Lundbeck Ltd (memantine) Wockhard UK (donezepil)
Mylan (galantamine, memantine) Zentiva UK (all but rivastigmine)
Stakeholder group: Patient/ carer groups
Memantine
4.17 Berichtsplan zum Bericht „Memantin bei Alzheimer Demenz“ [Auftrag A05-19C] Version 1.0 Stand: 24. August 2005, Report 
plan version1. Last accessed 10th January 2018
4.18 Amendment 1 zum Berichtsplan „Memantin bei Alzheimer Demenz“ [Auftrag A05/19C], 12.06.2006; Amendment 1 to the 
report plan version. Last accessed 10th January 2018
4.19 Amendment 2 zum Berichtsplan Memantin bei Alzheimer Demenz, Auftrag A05-19C  Version 1.0  Stand: 06.08.2007; 
Amendment 2 to the report plan version. Last accessed 10th January 2018
4.20 Memantin bei Alzheimer Demenz, Dokumentation and Würdigung der Stellungnahmen zum Berichtsplan, Auftrag A05-19C 
Version 1.0  Stand: 11.02.2008 ; documentation and appraisal of comments on the report plan version 1.0. Last accessed 10th 
January 2018
4.21 Memantin bei Alzheimer Demenz, Berichtsplan, Auftrag A05-19C  Version 2.0  Stand: 11.02.2008 ; Report plan version 2.0. Last 
accessed 10th January 2018
4.22 Memantin bei Alzheimer Demenz  Vorbericht (vorläufige Nutzenbewertung), Auftrag A05-19C  Version 1.0  Stand: 01.08.2008 ; 
Preliminary report. Last accessed 10th January 2018 
4.23 Memantin bei Alzheimer Demenz, Dokumentation und Würdigung der Stellungnahmen zum Vorbericht, Auftrag A05-19C 
Version 1.0  Stand: 28.04.2009.; Documentation and appraisal of comments on the preliminary report. Last accessed 10th January 
2018
4.24 IQWiG-Berichte – Jahr: 2009 Nr. 59  Memantin bei Alzheimer Demenz, Abschlussbericht, Auftrag A05-19C  Version 1.0  Stand: 
08.07.2009  Final report. Last accessed 10th January 2018
4.25 Tragende Gründe zum Beschluss des Gemeinsamen Bundesausschusses  über die Einleitung eines Stellungnahmeverfahrens zur 
Änderung  der Arzneimittel-Richtlinie (AM-RL): Anlage III – Übersicht der Verordnungseinschränkungen und –ausschlüsse 
Memantin, Vom 10. August 2010. Last accessed 10th January 2018
Zorginstituut Nederland, previously: College voor Zorgverzekeringen (CVZ), Netherlands
4.26 CFH rapport 07/11 memantine (Ebixa®), (2e)herbeoordeling, Op 2 april 2007 uitgebracht aan de minister van Volksgezondheid, 
Welzijn en Sport 
4.27 GVS-rapport 13/11 donepezil (hydrochloride) Aspen® Vastgesteld op 24 juni 2013, College voor zorgverzekeringen, Diemen.
4.28 Farmacotherapeutisch rapport rivastigmine (Exelon®) bij Parkinsondementie, 2006
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Afiya trust Mental Health Foundation
Alzheimer’s Society Muslim Council of Britain
Carers UK Muslim Health Network
Disability Rights UK Neurological Alliance
Equalities National Council Neurosupport
Innovations in Dementia South Asian Health Foundation
Leonard Cheshire Disability Specialised Healthcare Alliance
Stakeholder group: Professional associations
Association of British Neurologists Royal College of General Practitioners 
Association of Directors of Adult Social Services Royal College of Nursing
British Geriatrics Society Royal College of Pathologists
British Neuropathological Society Royal College of Physicians
British Neuropsychiatry Association Royal College of Psychiatrists
College of mental health Pharmacy Royal Pharmaceutical Society
Dementia Action Alliance Royal Society of Medicine
Institute of Neurology
Primary Care Neurology Society
United Kingdom Clinical Pharmacy Association
Others
Department of Health NHS South Eastern Hampshire CCG
NHS England Welsh Government
NHS Somerset CCG
GERMANY
Stakeholder English translation or description
Technology Assessment for Memantine
Bundesverband für Gesundheitsinformation und Verbraucherschutz e. V. Association for health information for the public and 
consumer protection (charity)
Deutsche Alzheimer Gesellschaft e.V German charity for Alzheimer
Deutsche Gesellschaft für Neurologie; Deutsche Gesellschaft für 
Psychiatrie, Psychotherapie und Nervenheilkunde
Professional association for psychiatry, psychotherapy and 
neurology
Hirnliga e.V. Charity for the brain; refers to Alzheimer 
Institut für angewandte Statistik Institute for applied statistics
Institut für Arzneimittelsicherheit in der Psychiatrie Institute for safety of psychiatric drugs 
Karolinska Institutet Swedish medical university
Kompetenznetz Demenz Network for researchers, clinicians, people living with 
Alzheimer and their families
Lundbeck GmbH Pharma company
Merz Pharmaceuticals GmbH Pharma company
Novartis Pharma GmbH Pharma company
The Research Institute for the Care of Older People (RICE) /
Verband Forschender Arzneimittelhersteller e. V. (VFA) Association of pharma companies involved in research
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Verein zur Förderung der Forschung auf dem Gebiet der 
experimentellen Neurologie
Association to promote research in neurology
Technology Assessment for Cholinesterase inhibitors




Merz Pharmaceuticals GmbH Pharma
Verband Forschender Arzneimittelhersteller e.V. Association of Pharma Companies involved in Research
University of Manchester University, England (UK)
Alzheimer-Ethik e.V. Charity for Alzheimer, founded by carers
Universitätsklinikum Freiburg University 
Deutsche Gesellschaft für Gerontologie und Geriatrie German Society of Gerontology and Geriatrics
Arznei-Telegramm News magazine about drugs 
Deutsche Gesellschaft f. Gerontopsychiatrie und –psychotherapie 
(DGGPP) e. V.
German Psychogeriatric Association
Deutsche Alzheimer Gesellschaft e. V. German Alzheimer Association (charity)
Universitätsklinikum Hamburg-Eppendorf Medical University in Hamburg, Germany
Kompetenznetz Demenzen Network for dementia
Hirnliga e.V. Charity for the Brain, specifically Dementia
Bezirkskrankenhaus Günzburg Hospital 
Institut für Klinische Pharmakologie, Klinikum Bremen-Mitte Pharmacological Institute, Medical university
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National Institute for 
Health and Care 
Excellence (NICE)
GERMANY
Institute for Quality and 







Advice about which drugs 
get funded based on cost-
effectiveness (=fourth 
hurdle)
Advice on added value 
used to inform price 
negotiations
Advice informs whether 
drug gets on positive list 
(which influences price)
Value assessment Cost-effectiveness Clinical benefit Clinical benefit; cost-




Guidance (manual) and 
reference case









Consultation with experts 
(including patient 
representatives)
Consultation with experts 
(including patient 
representatives)
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Table 2: Clinical scales used in studies identified in health technology assessments (HTAs) of 
Alzheimer’s disease drugs in England, Germany and The Netherlands
Drug covered in 
HTAs
Memantine Donezepil Galantamine Rivastigmine Different cholinesterase 
inhibitors
England



















































































Cognition ADAS-cog, SPI SIB, MMSE ADAS-cog, MMSE ADAS-cog, ADCS-CGIC 
MMSE
Page 48 of 49
Cambridge University Press
International Journal of Technology Assessment in Health Care
For Peer Review





NPI NPI NPI NPI-10
Global 
Assessment
CIBIC-PLUS GDS / /
Index of abbreviations used in Table: Activities of daily living (ADL); Alzheimer’s Disease Assessment Scale – cognitive subscale 
(ADAS-cog); Alzheimer’s Disease Cooperative Study – Activities of Daily Living (ADCS-ADL); the mild cognitive impairment ADL 
scale (ADCS-MCIADL); Allocation of caregiver time burden (ACTS); Behavioural Rating Scale for Geriatric Patients (BGP); 
Behavioral Pathology in Alzheimer's Disease Rating Scale (BEHAVE-AD) and the Behavioral Rating Scale for Dementias 
(BRSD); Behavioral Rating Scale for Geriatric Patients – Cognitive Subscale (BGP-C); Bristol Activities of daily Living Scale 
(BrADL); Clinical dementia rating (CDR); CDR sum of boxes (CDR-SB); Clinician’s Interview-based Impression of Change 
(CIBIC)-plus; Caregiver Activity Survey (CAS); Caregiving burden scale (CBS); Caregiver stress Scale (CSS); Caregiver-rated 
Modified Crichton Scale (CMCS); Disability Assessment for Dementia (DAD); Functional Assessment Staging (FAST); Goal 
Attainment Scale (GAS); Global Deterioration Scale (GDS); Gottfried, Brine and Steen scale (GBS); Interview for Deterioration 
in Daily Living Activities in Dementia (IDDD), subscale; Instrumental Activities of Daily Living (IADL)-plus; Japanese-Clinical 
Global Impression of Change (J-CGIC); Mini Mental State Examination (MMSE), Neuropsychiatric Inventory (NPI); NOSGER 
(Nurses’ Observation Scale for Geriatric Patients); Neuropsychiatric Inventory Caregiver Distress Scale (NPI-D); Neuropsychiatric 
inventory (NPI); Progressive Deterioration Scale (PDS); Severe Impairment Battery (SIB) scales; Physical Self-Maintenance 
Scale (PSMS)-plus; Severe Impairment Battery (SIB)
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Table 3 Prioritization of outcomes and outcome measures in health technology assessments (HTAs) of Alzheimer’s disease (AD) drugs






No economic modelling conducted
Not prioritized
No economic modelling conducted
Quality of life Prioritized
Derived from outcomes measured with clinical scales to 
inform the economic modelling
Not prioritized
Method requirements (e.g. 70% follow up rate) prevented 







Cognition (including Mini-Mental State Examination; 
MMSE), Activities of daily living (ADL) and multi-domain 
change prioritized
Prioritized
Global assessment outcomes less prioritized
Prioritized
Mini-Mental State Examination (MMSE) less 
prioritized / not accepted
Adverse effects Not prioritized
Formally included but not referred to in decision
Prioritized
Included and referred to in decision
Prioritized







Focus on evidence from randomised controlled trials that 
measure outcomes with clinical scales
Not prioritized
Focus on evidence from randomised controlled trials that 
measure outcomes with clinical scale
Not prioritized
Focus on evidence from randomised controlled trials 




Included as primary endpoint but lower priority than 
outcomes for person with AD; methodological challenges 
prevent influence of outcome on decisions
Not prioritized
Not considered responsibility of health care system; 
relevant only if impact on patient outcomes
Not prioritized
Potential role in economic modelling but not carried 




Included in economic modelling (by linking outcomes with 
clinical scales to non-AD data sets)
Not prioritized
Absence of trial evidence; method requirements also 
prevent influence of outcome on decisions
Not prioritized
Not included due to absence of trial evidence
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